Adriana Lai

TL;DR: Most patients with newly diagnosed Graves' disease have no ocular involvement and most patients (>80%) with no GO at baseline do not develop GO after an 18-month follow-up period, andRemission of mild GO occurs in the majority of cases.

TL;DR: An association between radioiodine therapy for Graves' disease and the development or worsening of Graves’ ophthalmopathy is widely quoted but there has been no systematic review of the evidence.

TL;DR: There seems to be a trend towards a decline in progression of GO, possibly due to a better control of risk factors (cigarette smoking, thyroid dysfunction, etc.) and a closer interaction between endocrinologists and ophthalmologists allowing an improved integrated management of thyroid and orbital disease.

TL;DR: Lower doses of oral prednisone are as effective as previously reported doses (0.3-0.5 mg/kg bw) and a shorter treatment period (6 wk) is probably sufficient, as the increase in bw is less using lower doses ofprednisone.

TL;DR: To determine how expert European thyroidologists assess and treat amiodarone‐induced thyrotoxicosis (AIT) is assessed and treated, a large number of experts believe it to be safe and effective to treat.